Pulmonx Corporation
HealthcareNASDAQ:LUNG · NASDAQ Global Select
-$0.05 today
Vol 0.23M · Avg 0.43M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$54.0M +4.2% | -$56.4M +7.3% | -$60.8M -3.3% | -$58.9M -21.1% | -$48.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.2M -22.7% | $1.5M -3.6% | $1.5M -61.3% | $4.0M +26.5% | $3.2M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 -100.0% | $49.0K +916.7% | -$6.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $23.0M +3.9% | $22.1M | $0 | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$1.9M -13.0% | -$1.7M +33.4% | -$2.6M +63.8% | -$7.1M +9.9% | -$7.8M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $1.1M +182.2% | -$1.3M +57.9% | -$3.1M -41.7% | -$2.2M +10.0% | -$2.4M | $592.6M | $1.3B | $626.2M |
| Inventory | -$765.0K -234.1% | -$229.0K -124.9% | $918.0K +125.2% | -$3.6M +43.7% | -$6.5M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $270.0K -88.1% | $2.3M +760.3% | -$345.0K -239.7% | $247.0K +183.9% | $87.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$2.5M -2.5% | -$2.4M -8951.9% | -$27.0K +98.2% | -$1.5M -253.9% | $963.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $22.3M +957.2% | $2.1M -1.4% | $2.1M -87.3% | $16.8M +41.0% | $11.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$32.4M -2.9% | -$31.5M +16.1% | -$37.6M +16.7% | -$45.1M -8.9% | -$41.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$452.0K +68.8% | -$1.4M -79.3% | -$807.0K +38.8% | -$1.3M +64.1% | -$3.7M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$5.7M +79.8% | -$27.9M +39.6% | -$46.2M +2.1% | -$47.2M +10.3% | -$52.6M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $36.6M -21.9% | $46.8M +4.1% | $45.0M +1.6% | $44.3M +342.8% | $10.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $30.5M +74.4% | $17.5M +970.8% | -$2.0M +52.5% | -$4.2M +90.9% | -$46.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$100.0K -5.3% | -$95.0K -100.5% | $19.9M +22980.5% | -$87.0K | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $1.0M | $0 | $0 -100.0% | $2.6M -42.8% | $4.5M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 +100.0% | -$27.0K -3.8% | -$26.0K | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $1.5M -2.4% | $1.5M | $0 | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $903.0K -33.7% | $1.4M -93.6% | $21.4M +765.7% | $2.5M -45.0% | $4.5M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$92.0K -221.1% | $76.0K +123.5% | $34.0K -76.6% | $145.0K +36.8% | $106.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$1.2M +90.9% | -$12.6M +30.6% | -$18.2M +61.1% | -$46.7M +43.7% | -$83.1M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$32.9M +0.3% | -$33.0M +14.1% | -$38.4M +17.3% | -$46.5M -3.0% | -$45.1M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Edap Tms S.a.
EDAP
$178.23M
Assertio Holdings, Inc.
NASDAQ:ASRT
$151.73M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Hyperfine, Inc.
NASDAQ:HYPR
$114.53M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
TELA Bio, Inc.
TELA
$38.50M
SEC Filings
Recent regulatory filings
No filings found.
Does LUNG generate free cash flow?
Pulmonx Corporation (LUNG) generated -$32,898,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does LUNG produce?
Operating cash flow was -$32,445,999.00, before capital expenditures of $452,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.